News

A low-dose course of glucocorticoid therapy results in similar outcomes as a higher-dose option in people with ANCA-associated vasculitis (AAV) and kidney involvement, though it may lower risk of serious infection, a study reports. “Our findings reinforce the safety and efficacy of reduced [glucocorticoid] as the initial [glucocorticoid] regimen…

Use of the experimental therapy BDB-001 helps adults with ANCA-associated vasculitis (AAV) achieve at least partial disease remission, while reducing the need for standard glucocorticoids. That’s according to new data from a Phase 1/2 clinical trial conducted in China. Glucocorticoids, also commonly called corticosteroids, are a standard AAV…

Combining two diagnostic systems used to classify cases of ANCA-associated vasculitis (AAV) in adults improved classification performance in a pediatric AAV patient population, according to a study in China. Identifying types of AAV is important to ensure effective clinical care in children, researchers noted. “Considering that distinct clinical…

Alivedx’s Mosaiq Aiplex vasculitis assay, a platform test for the two main self-reactive antibodies that drive most cases of ANCA-associated vasculitis (AAV), is now available for clinical use in the European Union (EU). The test is also able to detect self-reactive antibodies linked to another autoimmune condition marked…

Measuring circulating microRNAs — short RNA molecules that ultimately suppress gene activity — could offer doctors a less invasive way to monitor glomerulonephritis, a type of kidney inflammation, in ANCA-associated vasculitis (AAV), a study found. However, the study included a small number of patients, and testing microRNAs, or miRNAs,…

In ANCA-associated vasculitis (AAV), the involvement of the central nervous system (CNS), that is, the brain and spinal cord, is uncommon, but other factors may mimic CNS involvement, a study reports. These so-called mimickers can include AAV disease processes not related to the CNS, other conditions, and drug-related adverse…

Treatment with the immunosuppressants cyclophosphamide, azathioprine, or rituximab after ANCA-associated vasculitis (AAV) patients have experienced a brain bleed, or intracranial hemorrhage, is linked to better survival, according to a review of previously reported cases. “In our pooled analysis, we found that initiating [immunosuppressant] treatment after [brain bleeds] … was…

People with ANCA-associated vasculitis (AAV) affecting the kidneys who receive kidney transplants face higher long-term risks of transplant failure and death compared with those who undergo transplants for other reasons. That’s according to a study from France, which also found that the presence of ANCAs — self-reactive antibodies that…

Note: This story was updated on Aug. 6, 2025, to correct that proteinase 3 (PR3) and myeloperoxidase (MPO) are the enzymes targeted by AAV-causing antibodies. People with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis have elevated levels of certain immune-related proteins in their blood, a new study from Sweden reports. However, different…

Long-term treatment with Nucala (mepolizumab) is safe and effective in people with eosinophilic granulomatosis with polyangiitis (EGPA), the rarest type of ANCA-associated vasculitis (AAV), according to a meta-analysis of eight studies. After nearly two years of treatment, more than half of EGPA patients achieved remission, meaning they had…